281 related articles for article (PubMed ID: 35633050)
21. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
Panowski SH; Kuo TC; Zhang Y; Chen A; Geng T; Aschenbrenner L; Kamperschroer C; Pascua E; Chen W; Delaria K; Farias S; Bateman M; Dushin RG; Chin SM; Van Blarcom TJ; Yeung YA; Lindquist KC; Chunyk AG; Kuang B; Han B; Mirsky M; Pardo I; Buetow B; Martin TG; Wolf JL; Shelton D; Rajpal A; Strop P; Chaparro-Riggers J; Sasu BJ
Mol Cancer Ther; 2019 Nov; 18(11):2008-2020. PubMed ID: 31434693
[TBL] [Abstract][Full Text] [Related]
22. Anti-BCMA antibodies in the future management of multiple myeloma.
Gavriatopoulou M; Ntanasis-Stathopoulos I; Dimopoulos MA; Terpos E
Expert Rev Anticancer Ther; 2019 Apr; 19(4):319-326. PubMed ID: 30810049
[TBL] [Abstract][Full Text] [Related]
23. Effective anti-BCMA retreatment in multiple myeloma.
Gazeau N; Beauvais D; Yakoub-Agha I; Mitra S; Campbell TB; Facon T; Manier S
Blood Adv; 2021 Aug; 5(15):3016-3020. PubMed ID: 34351389
[TBL] [Abstract][Full Text] [Related]
24. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma.
Wang D; Wang J; Hu G; Wang W; Xiao Y; Cai H; Jiang L; Meng L; Yang Y; Zhou X; Hong Z; Yao Z; Xiao M; Chen L; Mao X; Zhu L; Wang J; Qiu L; Li C; Zhou J
Blood; 2021 May; 137(21):2890-2901. PubMed ID: 33512480
[TBL] [Abstract][Full Text] [Related]
25. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
Cohen AD; Mateos MV; Cohen YC; Rodriguez-Otero P; Paiva B; van de Donk NWCJ; Martin T; Suvannasankha A; De Braganca KC; Corsale C; Schecter JM; Varsos H; Deraedt W; Wang L; Vogel M; Roccia T; Xu X; Mistry P; Zudaire E; Akram M; Nesheiwat T; Pacaud L; Avivi I; San-Miguel J
Blood; 2023 Jan; 141(3):219-230. PubMed ID: 36095849
[TBL] [Abstract][Full Text] [Related]
27. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
Feng D; Sun J
Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
[TBL] [Abstract][Full Text] [Related]
28. Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents.
Del Giudice ML; Galimberti S; Buda G
Cancer Immunol Immunother; 2023 Dec; 72(12):3931-3937. PubMed ID: 37924369
[TBL] [Abstract][Full Text] [Related]
29. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
Front Immunol; 2021; 12():755866. PubMed ID: 34777368
[TBL] [Abstract][Full Text] [Related]
30. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
DiLillo DJ; Olson K; Mohrs K; Meagher TC; Bray K; Sineshchekova O; Startz T; Kuhnert J; Retter MW; Godin S; Sharma P; Delfino F; Lin J; Smith E; Thurston G; Kirshner JR
Blood Adv; 2021 Mar; 5(5):1291-1304. PubMed ID: 33651100
[TBL] [Abstract][Full Text] [Related]
31. An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy.
Quazi S
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e392-e404. PubMed ID: 34992008
[TBL] [Abstract][Full Text] [Related]
32. On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future.
Sunder-Plassmann V; Aksoy O; Lind J; Pecherstorfer M; Vallet S; Podar K
Expert Opin Pharmacother; 2022 Aug; 23(12):1425-1444. PubMed ID: 35829636
[TBL] [Abstract][Full Text] [Related]
33. Antibody treatment in multiple myeloma.
Maples KT; Johnson C; Lonial S
Clin Adv Hematol Oncol; 2021 Mar; 19(3):166-174. PubMed ID: 33739965
[TBL] [Abstract][Full Text] [Related]
34. Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management.
Markouli M; Ullah F; Unlu S; Omar N; Lopetegui-Lia N; Duco M; Anwer F; Raza S; Dima D
Curr Oncol; 2023 Jul; 30(7):6330-6352. PubMed ID: 37504327
[TBL] [Abstract][Full Text] [Related]
35. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
Mohan M; Chakraborty R; Bal S; Nellore A; Baljevic M; D'Souza A; Pappas PG; Berdeja JG; Callander N; Costa LJ
Br J Haematol; 2023 Dec; 203(5):736-746. PubMed ID: 37287117
[TBL] [Abstract][Full Text] [Related]
36. Integrating Immune Therapies for the Treatment of Multiple Myeloma.
Mikkilineni L; Sidana S
J Natl Compr Canc Netw; 2023 Dec; 21(12):1303-1311. PubMed ID: 38081142
[TBL] [Abstract][Full Text] [Related]
37. "Off-the-shelf" immunotherapies for multiple myeloma.
Mohammed T; Mailankody S
Semin Oncol; 2022 Feb; 49(1):60-68. PubMed ID: 35123801
[TBL] [Abstract][Full Text] [Related]
38. Comparison of infectious complications with BCMA-directed therapies in multiple myeloma.
Nath K; Shekarkhand T; Nemirovsky D; Derkach A; Costa BA; Nishimura N; Farzana T; Rueda C; Chung DJ; Landau HJ; Lahoud OB; Scordo M; Shah GL; Hassoun H; Maclachlan K; Korde N; Shah UA; Tan CR; Hultcrantz M; Giralt SA; Usmani SZ; Shahid Z; Mailankody S; Lesokhin AM
Blood Cancer J; 2024 May; 14(1):88. PubMed ID: 38821925
[TBL] [Abstract][Full Text] [Related]
39. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials.
Wang X; Zhao A; Zhu J; Niu T
Front Immunol; 2024; 15():1348955. PubMed ID: 38482019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
